-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shi Si Pharmaceutical Group Honored with the Title of Fastest-Growing Listed Biopharmaceutical Company
Category:
Time：2022-12-29
On December 28, at the "11th China Listed Companies Summit Forum," hosted by the mainstream financial media—Daily Economic News—the 2022 12th China Listed Companies Reputation Rankings were officially released. Shisi Pharmaceutical Group was honored with the title of "Most Promising Growth-Oriented Biopharmaceutical Listed Company."
On December 28, at the “11th China Listed Companies Summit Forum” hosted by Daily Economic News, a leading financial media outlet, the highly anticipated “12th China Listed Companies Reputation Rankings 2022” were officially released. Shisi Pharmaceutical Group was honored with the distinction of “Most Promising Growth-Oriented Biopharmaceutical Listed Company.”
It is reported that the “List of Top-Rated Listed Companies,” launched by the Daily Economic News, has been running for 12 years and has become one of the most influential events in the industry. The selection process for the “Top-Rated List” series involves four key stages: public nominations, big-data screening, model-based selection, and voting by institutions and the general public. Ultimately, more than a hundred outstanding companies are chosen from among thousands of listed firms and recognized accordingly. Among these awards, the “Most Promising Biopharmaceutical Listed Company” has long been regarded within the industry as one of the most prestigious and highly valued accolades, with fierce competition in the selection process. The successful inclusion of Shisi Pharmaceutical Group on this list fully demonstrates the company’s strong performance in areas such as innovation capability, market performance, commercial value, and growth potential, earning wide recognition from investors and capital markets.
As a major backbone enterprise in China’s pharmaceutical industry, in recent years, Shiyao Group has leveraged its own strengths and focused on the core theme of transformation, upgrading, quality enhancement, and efficiency improvement. Guided by innovative development, the group has actively implemented a “four-wheel-drive” synergy strategy encompassing generic drugs, active pharmaceutical ingredients, innovative drugs, and pharmaceutical packaging materials. By significantly increasing investment in innovation and relying on high-level innovation research platforms—such as the national-level enterprise technology center and the national-local joint engineering laboratory that integrate industry, academia, research, and application—the group has established a comprehensive, scientific, and well-defined path for technological innovation and product development. It continues to strategically position itself and exert strong efforts in areas such as first-to-market generic drugs, innovative drugs, specialized APIs, pharmaceutical packaging materials, and high-end complex formulations, thereby continuously empowering the company’s high-quality development. Since the beginning of this year, Shiyao Group has ranked among the top pharmaceutical companies nationwide in terms of both the efficiency and quantity of its specialty generic drug R&D, and its innovative drug research has made positive progress.
Since last year, Shisi Pharmaceutical Group has seized development opportunities, leveraging its innovation chain to accelerate the upgrading of its value chain, focusing on new growth areas, and building new competitive advantages. The group has sped up the market development of new products with high added value and promising market prospects. Its specialty formulations and active pharmaceutical ingredients are increasingly benefiting from both domestic and international dual-circulation strategies, strongly driving continuous growth in the company’s core business volume and revenue, and delivering impressive performance results time and again, significantly accelerating the company’s growth trajectory. In the recently released 2021 ranking of China’s Top 100 Pharmaceutical Companies, Shisi Pharmaceutical Group demonstrated remarkable progress and rapid growth in areas such as innovation capability, scale of development, market influence, and industry concentration, placing it at No. 59 on the list—a rise of 13 positions compared to its 2020 ranking.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license